Glomerular Injury / Proteinuria
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Agents’ overall severity
Each agent’s whole-drug severity grade, not the severity of this lesion specifically — an agent whose signature injury is elsewhere can still be graded severe here.
Agents’ overall reversibility
Agents’ onset window
How soon each agent’s kidney toxicity typically appears — a whole-drug tempo, not specific to this lesion.
Real-world reporting for this lesion
FAERS across all lesions →How disproportionately glomerular injury / proteinuria is reported for each agent in FAERS, against every other drug (reporting odds ratio, 95% CI; a signal needs the lower bound above 1, on at least 50 total reports for the agent) — a spontaneous-reporting signal, not incidence or proven causation. FAERS carries reporting and indication biases and has no denominator.
Documented in the atlas profile and carrying a FAERS signal — the strongest claim the atlas makes.
Documented in a profile with no reporting signal. 9 of 13 sit on a reportable term with enough reports, so FAERS could have flagged the lesion and did not; the rest are expected silences.
A real reporting signal that is not evidence for this drug-lesion pair: no MedDRA term names it, the naming subset asked alone came back flat, or the 2026-08 review attributed the reporting to the population, co-therapy, or class-level literature.
The terms that name this lesion are disproportionate, but no profile documents it for that agent. Most are echoed by a sibling agent in the same class. Leads for review, never lesions the atlas claims.
- PenpulimabPD-1 immune checkpoint inhibitor35.81 (14.56–88.06) · n=5 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- LenvatinibVEGFR TKI34.16 (32.45–35.96) · n=1,637 Reporting signal.
- FruquintinibVEGFR TKI26.50 (22.50–31.21) · n=150 Reporting signal.
- RamucirumabAnti-VEGFR2 antibody24.79 (21.69–28.33) · n=225 Reporting signal.
- BevacizumabAnti-VEGF antibody22.13 (21.36–22.93) · n=3,658 Reporting signal.
- RaltitrexedAntifolate (TS inhibitor) · FAERS only21.49 (13.62–33.92) · n=19 * Reporting signal, on terms consistent with the lesion rather than naming it.
- Tegafur-uracil (UFT)Antimetabolite (oral 5-FU prodrug) · FAERS only19.01 (8.45–42.76) · n=6 Reporting signal, fragile (few reports).
- AtezolizumabAnti-PD-L1 antibody16.62 (15.51–17.81) · n=851 Reporting signal.
- ToripalimabPD-1 immune checkpoint inhibitor12.08 (8.47–17.23) · n=31 * Reporting signal, on terms consistent with the lesion rather than naming it.
- SirolimusmTOR inhibitor9.55 (8.28–11.02) · n=192 Reporting signal.
- StreptozocinNitrosourea alkylator · FAERS only9.15 (2.93–28.58) · n=3 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- PembrolizumabPD-1 checkpoint inhibitor9.03 (8.53–9.56) · n=1,253 Reporting signal.
- CabozantinibVEGFR/MET TKI8.86 (8.17–9.60) · n=620 Reporting signal.
- SelpercatinibRET inhibitor8.56 (5.23–14.02) · n=16 Reporting signal.
- PentostatinPurine analog (ADA inhibitor) · FAERS only8.07 (3.61–18.04) · n=6 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- AxitinibVEGFR TKI7.85 (6.88–8.95) · n=226 Reporting signal.
- DinutuximabAnti-GD2 antibody · FAERS only7.85 (4.21–14.64) · n=10 * Reporting signal, on terms consistent with the lesion rather than naming it.
- TemsirolimusmTOR inhibitor7.03 (5.27–9.37) · n=47 * Reporting signal, on terms consistent with the lesion rather than naming it.
- RegorafenibVEGFR TKI6.86 (5.72–8.23) · n=118 Reporting signal.
- NedaplatinPlatinum agent · FAERS only6.77 (3.63–12.63) · n=10 * Reporting signal, on terms consistent with the lesion rather than naming it.
- FotemustineNitrosourea (alkylating) · FAERS only6.75 (2.17–21.05) · n=3 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- PazopanibVEGFR TKI6.38 (5.64–7.23) · n=254 Reporting signal.
- SorafenibVEGFR TKI5.91 (5.10–6.84) · n=181 Reporting signal.
- IrinotecanTopoisomerase I inhibitor · FAERS only5.90 (4.91–7.09) · n=115 Reporting signal.
- TivozanibVEGFR TKI5.62 (3.19–9.92) · n=12 * Reporting signal, on terms consistent with the lesion rather than naming it.
- AmsacrineTopoisomerase II inhibitor (acridine) · FAERS only5.53 (2.07–14.79) · n=4 Reporting signal, fragile (few reports).
- 5-FluorouracilPyrimidine analog · FAERS only5.48 (5.06–5.93) · n=630 Reporting signal.
- AvelumabAnti-PD-L1 antibody5.00 (3.44–7.25) · n=28 Reporting signal.
- PaclitaxelTaxane4.96 (4.61–5.34) · n=732 Reporting signal.
- TislelizumabPD-1 immune checkpoint inhibitor4.96 (3.84–6.41) · n=59 * Reporting signal, on terms consistent with the lesion rather than naming it.
- LorlatinibALK TKI4.68 (3.56–6.16) · n=52 Reporting signal.
- EverolimusmTOR inhibitor4.67 (4.19–5.19) · n=342 Reporting signal.
- VandetanibVEGFR/EGFR/RET TKI4.62 (2.31–9.26) · n=8 Reporting signal, fragile (few reports).
- Ziv-afliberceptVEGF trap4.23 (3.68–4.85) · n=205 Reporting signal.
- SunitinibVEGFR TKI4.10 (3.61–4.66) · n=238 Reporting signal.
- PamidronateBisphosphonate3.89 (2.58–5.86) · n=23 Reporting signal.
- GefitinibEGFR TKI3.80 (2.89–5.01) · n=51 Reporting signal.
- ErlotinibEGFR TKI3.77 (3.14–4.52) · n=116 * Reporting signal, on terms consistent with the lesion rather than naming it.
- PanitumumabAnti-EGFR antibody3.75 (3.05–4.62) · n=90 Reporting signal.
- GemcitabineNucleoside analog3.61 (3.21–4.05) · n=289 Reporting signal.
- NivolumabPD-1 checkpoint inhibitor2.92 (2.65–3.22) · n=426 Reporting signal.
- Mitomycin CAntitumor antibiotic2.56 (1.51–4.33) · n=14 Reporting signal.
- Belantamab mafodotinAntibody-drug conjugate (BCMA/MMAF)2.14 (1.11–4.12) · n=9 * Reporting signal, fragile (few reports), on terms consistent with the lesion rather than naming it.
- IpilimumabCTLA-4 checkpoint inhibitor2.00 (1.68–2.38) · n=131 Reporting signal.
- DasatinibBCR-ABL TKI1.95 (1.58–2.41) · n=86 Reporting signal.
- CetuximabAnti-EGFR antibody1.90 (1.54–2.34) · n=90 Reporting signal.
- BortezomibProteasome inhibitor1.84 (1.62–2.09) · n=247 Reporting signal.
- DurvalumabAnti-PD-L1 antibody1.80 (1.39–2.33) · n=58 * Reporting signal, on terms consistent with the lesion rather than naming it.
- NintedanibVEGFR/FGFR/PDGFR TKI1.61 (1.29–2.01) · n=79 Reporting signal.
- TrametinibMEK inhibitor1.48 (1.14–1.94) · n=54 * Reporting signal, on terms consistent with the lesion rather than naming it.
- DoxorubicinAnthracycline1.38 (1.20–1.58) · n=200 * Reporting signal, on terms consistent with the lesion rather than naming it.
- CemiplimabAnti-PD-1 antibody1.28 (0.48–3.42) · n=4 No reporting signal.
- CarfilzomibProteasome inhibitor1.13 (0.85–1.50) · n=48 No reporting signal.
- IbandronateBisphosphonate0.95 (0.61–1.49) · n=19 No reporting signal.
- Trastuzumab emtansine (T-DM1)Antibody-drug conjugate (HER2/DM1)0.95 (0.54–1.67) · n=12 No reporting signal.
- DostarlimabAnti-PD-1 antibody0.89 (0.29–2.75) · n=3 No reporting signal.
- IbrutinibBTK inhibitor0.37 (0.28–0.49) · n=45 No reporting signal.
- ClofarabinePurine analog0.29 (0.04–2.07) · n=1 No reporting signal.
reporting odds ratio (log) — no signal left of the dashed line at 1.0
No ratio — no GLOM reports, or too few (count in brackets): Adagrasib, Datopotamab deruxtecan (Dato-DXd)
No ratio — under 50 FAERS reports in total: Cosibelimab, Ivonescimab, Olverembatinib, Sugemalimab
No FAERS reports under the agent's name: Iobenguane I-131
Not matched in FAERS (the name cannot be told apart from other products): Interferon-α
All 56 agents documented with GLOM in the atlas are shown whether or not FAERS flags them, plus the 42 agents FAERS flags that the atlas does not document (marked “FAERS only”; the strongest 10 until you show all). Class composites (Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab); mTOR inhibitors (everolimus · temsirolimus); VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)) are not asked of FAERS; their member agents are ranked individually. 83 carry a reporting signal (filled dot: 95% CI lower bound above 1, on at least 50 reports for the agent); a signal on fewer than 10 reports of the disorder is hollow, on a dashed whisker. Grey marks are ratios that do not clear it. Signals are listed first, each group by ROR; * a signal carried by terms consistent with the lesion, not naming it. n = reports of the disorder for the agent. openFDA FAERS, as of 2026-11-15. A reporting signal, not incidence or causation, and no signal is not evidence of safety. Layout after the single-event rankings of Klomjit, Gupta et al.
Management approach
Full framework →Reduce proteinuria with RAAS blockade and blood-pressure control; hold or dose-reduce for heavy or worsening protein leak.
Drug-level levers
- Hold for nephrotic-range proteinuria or a rapidly rising UPCR; resume at a reduced dose after improvement.
- Dose-reduce for moderate proteinuria.
- Switch out of class if proteinuria is severe or persistent.
Pharmacologic toolkit
- RAAS blockade — ACE inhibitor or ARB to lower proteinuria and treat coexisting hypertension.
- Blood-pressure control — Tight control limits further glomerular stress.
When to biopsy
Consider for nephrotic-range proteinuria, hematuria, or atypical features to define the glomerular lesion (e.g., collapsing FSGS, TMA) and inform whether to continue therapy.
Monitoring
- · Urine protein/creatinine ratio at baseline and periodically
- · Blood pressure
- · Creatinine / eGFR and albumin
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
What the guidelines say
All guidelines →Society and consensus recommendations that speak to glomerular injury / proteinuria.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
Cited incidence across agents
Where the literature gives a representative glomerular injury / proteinuria figure, the agents ranked highest first. Hover a dot for its cited note.
Offending agents
Signature offenders
15Agents for which glomerular injury / proteinuria is the defining renal lesion.
Also associated
44Agents that cause glomerular injury / proteinuria as a secondary pattern alongside a different signature lesion.